Volume 28, Issue 2 - Generics and biosimilars

Same but different: Basic tools for biosimilar and generic pharmacovigilance writing

Authors: Tiziana von Bruchhausen, Kerstin Prechtel, Stefanie Rechtsteiner

Abstract

Download the full article

References

1. Guideline on Similar Biological Medicinal Products. European Medicines Agency and Committee for Medicinal Products for Human Use (CHMP).23 Oct 2014 [cited 21 Jan 2019]. Available from: Available from: https://www.ema.europa.eu/documents/ scientific-guideline/guideline-similarbiological- medicinal-products-rev1_en.pdf.
2. Sydow S, Grajer KH. Biosimilars: Die Sicht der Innovatoren. Pharm. Unserer Zeit. 6/2012 (41)
3. Guideline on Good Pharmacovigilance Practices (GVP) – Annex I (Rev 4). European Medicines Agency and Heads of Medicines Agencies. 09 Oct 2017 [cited 05 Feb 2019]. Available from: Available from: https://www.ema.europa.eu/documents/ scientific-guideline/guideline-goodpharmacovigilance- practices-annex-idefinitions- rev-4_en.pdf .
4. EMA homepage. European Medicines Agency. [cited 05 Feb 2019]. Available from: Available from: https://www.ema.europa.eu/en/ human-regulatory/marketingauthorisation/ biosimilar-medicinesmarketing- authorisation
5. GaBI homepage. Generics and Biosimilars Initiative. [cited 05 Feb 2019]. Available from: Available from: http://gabionline.net/ Generics/ General/WHO-definitions-of-generics.
6. International conference on harmonisation of technical Requirements for registration of pharmaceuticals for human use – ICH Harmonised Tripartite Guideline – Development Safety Update Report E2F. Current Step 4 version, dated 17 August 2010. Available from: https://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/ Guidelines/Efficacy/E2F/Step4/E2F_ Step_4.pdf.
7. Guideline on Good Pharmacovigilance Practices (GVP) Module V – Risk manage - ment systems (Rev 2). European Medicines Agency and Heads of Medicines Agencies; 28 Mar 2017 [cited 19 Feb 2019]. Available from: Available from: https://www.ema. europa.eu/ documents/ scientific-guideline/guidelinegood- pharmacovigilance-practices-modulev- risk-management-systems-rev-2_en.pdf.
8. Guideline on Good Pharmacovigilance Practices (GVP) - Product- or Population- Specific Considerations II: Biological medicinal products. European Medicines Agency and Heads of Medicines Agencies; 04 Aug 2016 [cited 17 Jan 2019]. Available from: Available from: https://www.ema.europa.eu/ documents/scientific-guideline/guidelinegood- pharmacovigilance-practices-gvpproduct- population-specific-considerations -ii_en-0.pdf.
9. Guideline on Good Pharmacovigilance Practices (GVP) Module VII – Periodic safety update report (Rev 1). European Medicines Agency and Heads of Medicines Agencies; 09 Dec 2018 [cited 17 Jan 2019]. Available from: Available from: https://www.ema.europa. eu/documents/scientific-guideline/ guideline-good-pharmacovigilancepractices- gvp-module-vii-periodic-safetyupdate- report_en.pdf.
10. ICH guideline E2C (R2) on periodic benefit-risk evaluation report (PBRER). European Medicines Agency. January 2013 [cited 22 Jan 2019]. Available from: Available from: https://www.ema.europa.eu/documents/ regulatory-procedural-guideline/ international-conference-harmonisationtechnical- requirements-registrationpharmaceuticals- human-use_en-0.pdf.
11. Explanatory Note to GVP Module VII. European Medicines Agency and Human Medicines Evaluation Division; 31 Oct 2017 [cited 22 Jan 2019]. Available from: Available from: https://www.ema.europa.eu/documents/ scientific-guideline/guideline-goodpharmacovigilance- practices-gvp-modulevii- periodic-safety-update-reportexplanatory_ en.pdf.